ivabradine (corlanor) Report issue

Small molecule Approved FDA First in Class Fast Track FDA Priority Review FDA

Active Ingredient History

  • Now
Ivabradine (CORLANOR®) is a hyperpolarization-activated cyclic nucleotide-gated channel blocker that reduces the spontaneous pacemaker activity of the cardiac sinus node by selectively inhibiting the If-current, resulting in heart rate reduction at concentrations that do not affect other cardiac ionic currents. Specific heart-rate lowering with ivabradine (CORLANOR®) reduces myocardial oxygen demand, simultaneously improving oxygen supply. It has no negative inotropic or lusitropic effects, preserving ventricular contractility, and does not change any major electrophysiological parameters unrelated to heart rate.   NCATS

  • SMILES: COc1cc2CCN(CCCN(C)C[C@H]3Cc4cc(OC)c(OC)cc34)C(=O)Cc2cc1OC
  • Mol. Mass: 468.59
  • ALogP: 3.31
  • ChEMBL Molecules:
More Chemistry

Drug Pricing (per unit)

United States

$5.4307 - $7.9354
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

3-[3-({[(7s)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}(methyl)amino)propyl]-7,8-dimethoxy-2,3,4,5-tetrahydro-1h-3-benzazepin-2-one | 7,8-dimethoxy-3-(3-(((4,5-dimethoxybenzocyclobutan-1-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-2h-benzazepin-2-one | amg-998 | coraxan | corlanor | corlentor | ivabradin | ivabradina | ivabradine | ivabradine hcl | ivabradine hydrochloride | ivabradinum | procoralan | s 16257 | s-16257 | s 16257-2 | s-16257-2 | s 16260-2 | s-16260-2


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue